JPS5229888B2
(zh)
|
1972-02-01 |
1977-08-04 |
|
|
US4769320A
(en)
|
1982-07-27 |
1988-09-06 |
New England Medical Center Hospitals, Inc. |
Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
|
CA1209907A
(en)
*
|
1982-04-12 |
1986-08-19 |
Richard M. Bartholomew |
Method of affinity purification employing monoclonal antibodies
|
JPS58201994A
(ja)
|
1982-05-21 |
1983-11-25 |
Hideaki Hagiwara |
抗原特異的ヒト免疫グロブリンの生産方法
|
US4689299A
(en)
*
|
1982-09-30 |
1987-08-25 |
University Of Rochester |
Human monoclonal antibodies against bacterial toxins
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
JPS6088703A
(ja)
|
1983-10-18 |
1985-05-18 |
新日本製鐵株式会社 |
耐重荷重性舗装体
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
JPH06104071B2
(ja)
|
1986-08-24 |
1994-12-21 |
財団法人化学及血清療法研究所 |
第▲ix▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
|
US4801687A
(en)
*
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
JPS63149900A
(ja)
|
1986-12-15 |
1988-06-22 |
Toshiba Corp |
半導体メモリ
|
US4851341A
(en)
|
1986-12-19 |
1989-07-25 |
Immunex Corporation |
Immunoaffinity purification system
|
JPH01144991A
(ja)
|
1987-12-02 |
1989-06-07 |
Kagaku Oyobi Ketsusei Riyouhou Kenkyusho |
血液凝固第8因子の精製方法
|
US5670373A
(en)
*
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
RO105652B1
(ro)
|
1988-09-28 |
1992-11-30 |
Lilly Co Eli |
Procedeu de reducere a heterogenitatii anticorpilor monoclonali
|
US5126250A
(en)
*
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
CA2006684C
(en)
|
1988-12-30 |
1996-12-17 |
Charles T. Esmon |
Monoclonal antibody against protein c
|
US5202253A
(en)
|
1988-12-30 |
1993-04-13 |
Oklahoma Medical Research Foundation |
Monoclonal antibody specific for protein C and antibody purification method
|
JPH0636741B2
(ja)
|
1989-11-08 |
1994-05-18 |
帝人株式会社 |
ヒト・プロテインcの分離方法
|
DE69130561T2
(de)
|
1990-02-16 |
1999-06-24 |
Boston Biomed Res Inst |
Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen
|
US5130129A
(en)
|
1990-03-06 |
1992-07-14 |
The Regents Of The University Of California |
Method for enhancing antibody transport through capillary barriers
|
WO1992020791A1
(en)
|
1990-07-10 |
1992-11-26 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
WO1992003918A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
GB9022547D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Purified immunoglobulin
|
WO1992019759A1
(en)
|
1991-04-25 |
1992-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin 6 receptor
|
US5468634A
(en)
*
|
1991-06-24 |
1995-11-21 |
The University Of North Carolina At Chapel Hill |
Axl oncogene
|
JP3087857B2
(ja)
|
1991-07-04 |
2000-09-11 |
東洋紡績株式会社 |
交編編地の染色処理方法
|
AU665025B2
(en)
|
1991-09-23 |
1995-12-14 |
Cambridge Antibody Technology Limited |
Production of chimeric antibodies - a combinatorial approach
|
ATE275198T1
(de)
|
1991-12-02 |
2004-09-15 |
Medical Res Council |
Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
|
EP0746609A4
(en)
|
1991-12-17 |
1997-12-17 |
Genpharm Int |
NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
EP0656941B1
(en)
|
1992-03-24 |
2005-06-01 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
AU4116793A
(en)
|
1992-04-24 |
1993-11-29 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
NZ255101A
(en)
|
1992-07-24 |
1997-08-22 |
Cell Genesys Inc |
A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
|
BR9204244A
(pt)
|
1992-10-26 |
1994-05-03 |
Cofap |
Ferro fundido cinzento
|
EP0671951A4
(en)
|
1992-12-01 |
1997-05-21 |
Protein Design Labs Inc |
HUMANIZED ANTIBODIES REACTING WITH L-SELECTIN.
|
US7393682B1
(en)
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
CA2157577C
(en)
|
1993-03-19 |
2009-11-17 |
Se-Jin Lee |
Growth differentiation factor-8
|
WO1994029471A1
(en)
|
1993-06-10 |
1994-12-22 |
Genetic Therapy, Inc. |
Adenoviral vectors for treatment of hemophilia
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
FR2707189B1
(fr)
|
1993-07-09 |
1995-10-13 |
Gradient Ass |
Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
|
GB9314271D0
(en)
|
1993-07-09 |
1993-08-18 |
Inst Of Cancer The Research |
Cell growth factor receptors
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
CA2177988A1
(en)
|
1993-12-03 |
1995-06-08 |
Kazuo Higuchi |
Expression vector for preparing an anti-body-variable-region library
|
AU690171B2
(en)
|
1993-12-03 |
1998-04-23 |
Medical Research Council |
Recombinant binding proteins and peptides
|
JPH07177572A
(ja)
|
1993-12-20 |
1995-07-14 |
Matsushita Electric Ind Co Ltd |
コードレス電話の留守番方法
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
US5945311A
(en)
*
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
DE122009000068I2
(de)
|
1994-06-03 |
2011-06-16 |
Ascenion Gmbh |
Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
|
US8017121B2
(en)
*
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
WO1996001653A1
(en)
|
1994-07-11 |
1996-01-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the specific coagulation of vasculature
|
US6048972A
(en)
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
JP3865418B2
(ja)
|
1994-07-13 |
2007-01-10 |
中外製薬株式会社 |
ヒトインターロイキン−8に対する再構成ヒト抗体
|
WO1996002576A1
(fr)
|
1994-07-13 |
1996-02-01 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps humain reconstitue contre l'interleukine-8 humaine
|
TW416960B
(en)
|
1994-07-13 |
2001-01-01 |
Chugai Pharmaceutical Co Ltd |
Reshaped human antibody to human interleukin-8
|
CN1156460A
(zh)
|
1994-07-13 |
1997-08-06 |
中外制药株式会社 |
抗人白细胞介素-8的重构人抗体
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
RU2147443C1
(ru)
|
1994-10-07 |
2000-04-20 |
Чугаи Сейяку Кабусики Кайся |
Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента
|
EP0791359A4
(en)
|
1994-10-21 |
2002-09-11 |
Chugai Pharmaceutical Co Ltd |
MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
|
US5876950A
(en)
|
1995-01-26 |
1999-03-02 |
Bristol-Myers Squibb Company |
Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
EP1978033A3
(en)
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5830478A
(en)
|
1995-06-07 |
1998-11-03 |
Boston Biomedical Research Institute |
Method for delivering functional domains of diphtheria toxin to a cellular target
|
ES2233974T3
(es)
*
|
1995-09-11 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
AU720232B2
(en)
|
1996-07-19 |
2000-05-25 |
Amgen, Inc. |
Analogs of cationic proteins
|
US7247302B1
(en)
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
CA2262405A1
(en)
|
1996-08-02 |
1998-02-12 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
US6903194B1
(en)
|
1996-09-26 |
2005-06-07 |
Chungai Seiyaku Kabushiki Kaisha |
Antibody against human parathormone related peptides
|
US6025158A
(en)
|
1997-02-21 |
2000-02-15 |
Genentech, Inc. |
Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
ES2312184T3
(es)
|
1997-03-21 |
2009-02-16 |
Chugai Seiyaku Kabushiki Kaisha |
Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
FR2761994B1
(fr)
|
1997-04-11 |
1999-06-18 |
Centre Nat Rech Scient |
Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
|
JP4086908B2
(ja)
|
1997-04-17 |
2008-05-14 |
アムジエン・インコーポレーテツド |
安定かつ活性なヒトOBタンパク質と抗体Fc鎖とのコンジュゲートを含む組成物および方法
|
ES2246069T3
(es)
|
1997-05-02 |
2006-02-01 |
Genentech, Inc. |
Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
|
US5980893A
(en)
|
1997-07-17 |
1999-11-09 |
Beth Israel Deaconess Medical Center, Inc. |
Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
|
US20020187150A1
(en)
*
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
WO1999008707A1
(fr)
|
1997-08-15 |
1999-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Preventifs et/ou medicaments contre le lupus erythemateux systemique, contenant un anticorps anti-recepteur d'il-6 comme ingredient actif
|
CA2305712A1
(en)
*
|
1997-10-03 |
1999-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Natural humanized antibody
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
CN100374159C
(zh)
|
1998-03-17 |
2008-03-12 |
中外制药株式会社 |
一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
CA2341029A1
(en)
*
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
US6475718B2
(en)
|
1998-09-08 |
2002-11-05 |
Schering Aktiengesellschaft |
Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
|
US6329511B1
(en)
*
|
1998-12-01 |
2001-12-11 |
Protein Design Labs, Inc. |
Humanized antibodies to γ-interferon
|
EP1051432B1
(en)
|
1998-12-08 |
2007-01-24 |
Biovation Limited |
Method for reducing immunogenicity of proteins
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
AU2006225302B2
(en)
|
1999-03-25 |
2010-08-12 |
AbbVie Deutschland GmbH & Co. KG |
Human antibodies that bind human IL-12 and methods for producing
|
ES2571230T3
(es)
|
1999-04-09 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
EP1188830B1
(en)
|
1999-06-02 |
2010-01-20 |
Chugai Seiyaku Kabushiki Kaisha |
Novel hemopoietin receptor protein ,nr10
|
US6331642B1
(en)
|
1999-07-12 |
2001-12-18 |
Hoffmann-La Roche Inc. |
Vitamin D3 analogs
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US20040058393A1
(en)
|
2000-04-17 |
2004-03-25 |
Naoshi Fukishima |
Agonist antibodies
|
JP2004511426A
(ja)
|
2000-05-03 |
2004-04-15 |
ミュンヘン バイオテク アーゲー |
活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬
|
AU6842701A
(en)
*
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
AU2011244851A1
(en)
|
2000-07-27 |
2011-11-24 |
The John Hopkins University School Of Medicine |
Promyostatin peptides and methods of using same
|
CA2421447C
(en)
|
2000-09-08 |
2012-05-08 |
Universitat Zurich |
Collections of repeat proteins comprising repeat modules
|
CN102311986B
(zh)
|
2000-10-06 |
2015-08-19 |
协和发酵麒麟株式会社 |
产生抗体组合物的细胞
|
EP2113516B1
(en)
|
2000-10-10 |
2014-05-21 |
Genentech, Inc. |
Antibodies against C5 inhibiting type II endothelial cell activation
|
EP2141243A3
(en)
|
2000-10-16 |
2010-01-27 |
Brystol-Myers Squibb Company |
Protein scaffolds for antibody mimics and other binding proteins
|
CN1259973C
(zh)
|
2000-10-25 |
2006-06-21 |
中外制药株式会社 |
含有il-6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
|
AU2000279625A1
(en)
*
|
2000-10-27 |
2002-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2002307037B2
(en)
|
2001-04-02 |
2008-08-07 |
Biogen Idec Inc. |
Recombinant antibodies coexpressed with GnTIII
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
UA83791C2
(ru)
*
|
2001-04-13 |
2008-08-26 |
Байоджен Айдек Ма Инк. |
Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
|
US7667004B2
(en)
*
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
WO2003000883A1
(en)
*
|
2001-06-22 |
2003-01-03 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitors containing anti-glypican 3 antibody
|
EP1399484B1
(en)
|
2001-06-28 |
2010-08-11 |
Domantis Limited |
Dual-specific ligand and its use
|
US20040161741A1
(en)
|
2001-06-30 |
2004-08-19 |
Elazar Rabani |
Novel compositions and processes for analyte detection, quantification and amplification
|
ES2283594T5
(es)
|
2001-08-17 |
2016-03-15 |
Genentech, Inc. |
Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US20030190705A1
(en)
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
IL161968A0
(en)
|
2001-11-14 |
2005-11-20 |
Centocor Inc |
Anti-il-6 antibodies, compositions, methods and uses
|
DE60226641D1
(de)
|
2001-12-03 |
2008-06-26 |
Amgen Fremont Inc |
Antikörperkategorisierung auf der grundlage von bindungseigenschaften
|
JP4063769B2
(ja)
|
2001-12-28 |
2008-03-19 |
中外製薬株式会社 |
タンパク質安定化方法
|
PT1576112E
(pt)
*
|
2002-01-18 |
2012-05-25 |
Zymogenetics Inc |
Multímeros de receptor de citocina zcytor17
|
CN100575482C
(zh)
*
|
2002-01-18 |
2009-12-30 |
津莫吉尼蒂克斯公司 |
新的细胞因子zcytor17配体
|
JP2006506943A
(ja)
|
2002-02-11 |
2006-03-02 |
ジェネンテック・インコーポレーテッド |
抗原結合速度の大きい抗体変異体
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
JP4468803B2
(ja)
|
2002-05-31 |
2010-05-26 |
ジーイー・ヘルスケア・バイオ−サイエンシーズ・アーベー |
結合剤を基板表面にカップリングさせる方法
|
US20050130224A1
(en)
*
|
2002-05-31 |
2005-06-16 |
Celestar Lexico- Sciences, Inc. |
Interaction predicting device
|
EP1512015B1
(en)
|
2002-06-12 |
2009-03-25 |
Genencor International, Inc. |
Methods for improving a binding characteristic of a molecule
|
US20060141456A1
(en)
|
2002-06-12 |
2006-06-29 |
Cynthia Edwards |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
EP1382969A1
(en)
|
2002-07-17 |
2004-01-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Diagnosis and prevention of cancer cell invasion
|
DE60331778D1
(de)
|
2002-09-16 |
2010-04-29 |
Univ Johns Hopkins |
Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
|
DK2345671T3
(en)
|
2002-09-27 |
2016-02-15 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
SI1562972T1
(sl)
|
2002-10-15 |
2010-12-31 |
Facet Biotech Corp |
ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO
|
AU2003285874A1
(en)
*
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
ATE527278T1
(de)
|
2002-12-16 |
2011-10-15 |
Genmab As |
Humane monoklonale antikörper gegen interleukin 8 (il-8)
|
EP1578801A2
(en)
|
2002-12-27 |
2005-09-28 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
EP1601697B1
(en)
|
2003-02-28 |
2007-05-30 |
Lonza Biologics plc |
Antibody purification by Protein A and ion exchange chromatography
|
KR20060026004A
(ko)
|
2003-02-28 |
2006-03-22 |
안티제닉스 아이엔씨 |
당단백질 및 항원성 분자의 올리고머화를 조장하는 렉틴의용도
|
US20040223970A1
(en)
*
|
2003-02-28 |
2004-11-11 |
Daniel Afar |
Antibodies against SLC15A2 and uses thereof
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
WO2004091543A2
(en)
|
2003-03-04 |
2004-10-28 |
Alexion Pharmaceuticals, Inc. |
Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
|
EP1606316A2
(en)
|
2003-03-24 |
2005-12-21 |
ZymoGenetics, Inc. |
Anti-il-20 antibodies and binding partners and methods of using in inflammation
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
UA85055C2
(ru)
|
2003-06-02 |
2008-12-25 |
Уайт |
Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
|
JP2005004970A
(ja)
|
2003-06-09 |
2005-01-06 |
Hitachi Cable Ltd |
複合ケーブルおよびこれを用いた先行配線システム
|
WO2004113387A2
(en)
|
2003-06-24 |
2004-12-29 |
Merck Patent Gmbh |
Tumour necrosis factor receptor molecules with reduced immunogenicity
|
US7011924B2
(en)
|
2003-07-30 |
2006-03-14 |
Hynix Semiconductor Inc. |
Photoresist polymers and photoresist compositions comprising the same
|
WO2005023193A2
(en)
|
2003-09-04 |
2005-03-17 |
Interleukin Genetics, Inc. |
Methods of treating endometriosis
|
AU2004273791A1
(en)
*
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
JPWO2005035754A1
(ja)
|
2003-10-14 |
2006-12-21 |
中外製薬株式会社 |
機能蛋白質を代替する二種特異性抗体
|
JP2007531707A
(ja)
|
2003-10-15 |
2007-11-08 |
ピーディーエル バイオファーマ, インコーポレイテッド |
IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
|
NZ546557A
(en)
|
2003-10-17 |
2010-01-29 |
Chugai Pharmaceutical Co Ltd |
Therapeutic agent for mesothelioma comprising interleukin-6
|
US20050164301A1
(en)
|
2003-10-24 |
2005-07-28 |
Avidia Research Institute |
LDL receptor class A and EGF domain monomers and multimers
|
AU2004291341B2
(en)
*
|
2003-11-05 |
2010-08-05 |
Ares Trading S.A. |
Process for the purification of IL-18 binding protein
|
AU2004290070A1
(en)
*
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
US20050142133A1
(en)
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
CA2548817A1
(en)
|
2003-12-04 |
2005-06-23 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
KR101374514B1
(ko)
*
|
2003-12-10 |
2014-03-13 |
메다렉스, 인코포레이티드 |
Ip―10 항체 및 그의 용도
|
AR048210A1
(es)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
AU2004312411B8
(en)
|
2003-12-31 |
2011-11-24 |
Schering-Plough Pty. Limited |
Neutralizing epitope-based growth enhancing vaccine
|
ATE437184T1
(de)
|
2004-01-12 |
2009-08-15 |
Applied Molecular Evolution |
Varianten der fc-region
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
US20070116710A1
(en)
|
2004-02-03 |
2007-05-24 |
Leonard Bell |
Methods of treating hemolytic anemia
|
ATE464908T1
(de)
|
2004-02-11 |
2010-05-15 |
Warner Lambert Co |
Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
|
WO2005094446A2
(en)
|
2004-03-23 |
2005-10-13 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
EP1737890A2
(en)
*
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
US8398980B2
(en)
*
|
2004-03-24 |
2013-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Subtypes of humanized antibody against interleuken-6 receptor
|
KR20070035482A
(ko)
|
2004-03-24 |
2007-03-30 |
추가이 세이야쿠 가부시키가이샤 |
인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제
|
US20050260711A1
(en)
*
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
MXPA06011796A
(es)
|
2004-04-16 |
2007-05-07 |
Macrogenics Inc |
Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
|
KR101699142B1
(ko)
*
|
2004-06-18 |
2017-01-23 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
EP1773391A4
(en)
|
2004-06-25 |
2009-01-21 |
Medimmune Inc |
INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
|
DE102004032634A1
(de)
|
2004-07-06 |
2006-02-16 |
Sms Demag Ag |
Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
|
WO2006023144A2
(en)
|
2004-07-06 |
2006-03-02 |
Bioren Inc. |
Look-through mutagenesis for developing altered polypeptides with enhanced properties
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
EP1771483A1
(en)
*
|
2004-07-20 |
2007-04-11 |
Symphogen A/S |
Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
|
KR100864549B1
(ko)
|
2004-08-04 |
2008-10-20 |
어플라이드 몰리큘라 에볼류션, 인코포레이티드 |
변이체 fc 영역
|
CA2577329A1
(en)
|
2004-08-16 |
2006-03-02 |
Medimmune, Inc. |
Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
|
KR20080080675A
(ko)
|
2004-08-19 |
2008-09-04 |
제넨테크, 인크. |
변경된 이펙터 기능을 갖는 폴리펩티드 변이체
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
AU2005299716B2
(en)
*
|
2004-10-22 |
2012-09-06 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
KR20070090890A
(ko)
|
2004-10-22 |
2007-09-06 |
메디뮨 인코포레이티드 |
Hmgb1에 대한 고 친화성 항체 및 이의 사용 방법
|
WO2007084253A2
(en)
|
2005-11-28 |
2007-07-26 |
Medimmune, Inc. |
High affinity antibodies against hmgb1 and methods of use thereof
|
CA2585891A1
(en)
|
2004-10-29 |
2006-05-11 |
Medimmune, Inc. |
Methods of preventing and treating rsv infections and related conditions
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
CN101098890B
(zh)
|
2004-11-12 |
2012-07-18 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
KR101027427B1
(ko)
|
2004-11-12 |
2011-04-11 |
젠코어 인코포레이티드 |
FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체
|
US20070135620A1
(en)
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8329186B2
(en)
|
2004-12-20 |
2012-12-11 |
Isu Abxis Co., Ltd |
Treatment of inflammation using BST2 inhibitor
|
US20090061485A1
(en)
|
2004-12-22 |
2009-03-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
|
JP2008525327A
(ja)
|
2004-12-23 |
2008-07-17 |
ノヴォ ノルディスク アクティーゼルスカブ |
抗体結合親和性リガンド
|
US20090087478A1
(en)
|
2004-12-27 |
2009-04-02 |
Progenics Pharmaceuticals (Nevada), Inc. |
Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
|
CA2591059C
(en)
|
2004-12-28 |
2018-11-06 |
Innate Pharma |
Monoclonal antibodies against nkg2a
|
WO2006076594A2
(en)
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
GB0502358D0
(en)
|
2005-02-04 |
2005-03-16 |
Novartis Ag |
Organic compounds
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
US20060182743A1
(en)
*
|
2005-02-14 |
2006-08-17 |
Janine Bilsborough |
Methods of treating skin disorders using an IL-31RA antagonist
|
EP1869192B1
(en)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Framework-shuffling of antibodies
|
WO2006106903A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2構造異性体
|
CA2602663A1
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc variants with optimized properties
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
SI1876236T1
(sl)
|
2005-04-08 |
2014-11-28 |
Chugai Seiyaku Kabushiki Kaisha |
Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi
|
SI1874819T1
(sl)
*
|
2005-04-18 |
2015-09-30 |
Amgen Research (Munich) Gmbh |
Protitelesni nevtralizatorji humanega faktorja stimulacije kolonij granulocitov makrofagov
|
MX2007013058A
(es)
|
2005-04-20 |
2008-02-22 |
Amgen Fremont Inc |
Anticuerpos monoclonales de alta afinidad completamente humanos para interleucina-8 y epitopes para dichos anticuerpos.
|
DOP2006000093A
(es)
|
2005-04-25 |
2007-01-31 |
Pfizer |
Anticuerpos contra miostatina
|
WO2006116260A2
(en)
|
2005-04-26 |
2006-11-02 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
EP1896503B1
(en)
|
2005-05-31 |
2014-10-29 |
Board of Regents, The University of Texas System |
IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
|
AU2006256041B2
(en)
*
|
2005-06-10 |
2012-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
AU2006268227A1
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc |
Optimized anti-Ep-CAM antibodies
|
UA97469C2
(uk)
|
2005-07-25 |
2012-02-27 |
Емерджент Продакт Дівелопмент Сіетл, Елелсі |
Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
|
US8217147B2
(en)
|
2005-08-10 |
2012-07-10 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
PT2407486T
(pt)
|
2005-08-19 |
2018-02-21 |
Univ Pennsylvania |
Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
JP5052517B2
(ja)
|
2005-10-06 |
2012-10-17 |
イーライ リリー アンド カンパニー |
抗ミオスタチン抗体
|
UA92504C2
(en)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
WO2007043641A1
(ja)
|
2005-10-14 |
2007-04-19 |
Fukuoka University |
膵島移植における移植膵島障害抑制剤
|
BRPI0617664B8
(pt)
|
2005-10-21 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
|
EP2465870A1
(en)
*
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
AR057579A1
(es)
|
2005-11-23 |
2007-12-05 |
Merck & Co Inc |
Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
AR057941A1
(es)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
Agentes terapeuticos para el cancer de prostata
|
EP1973576B1
(en)
|
2005-11-28 |
2019-05-15 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
BRPI0619747B8
(pt)
|
2005-12-12 |
2021-05-25 |
Ac Immune Sa |
método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide
|
US9084777B2
(en)
*
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
PL1971366T3
(pl)
|
2005-12-29 |
2015-01-30 |
Janssen Biotech Inc |
Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
|
AU2007249713A1
(en)
|
2006-01-10 |
2007-11-22 |
Zymogenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists
|
EP3135298B1
(en)
|
2006-01-27 |
2018-06-06 |
Keio University |
Therapeutic agents for diseases involving choroidal neovascularization
|
US20080071063A1
(en)
|
2006-02-03 |
2008-03-20 |
Medimmune, Inc. |
Protein Formulations
|
US20070190056A1
(en)
|
2006-02-07 |
2007-08-16 |
Ravi Kambadur |
Muscle regeneration compositions and uses therefor
|
JP4179517B2
(ja)
|
2006-02-21 |
2008-11-12 |
プロテノバ株式会社 |
イムノグロブリン親和性リガンド
|
WO2007097361A1
(ja)
|
2006-02-21 |
2007-08-30 |
Protenova Co., Ltd. |
イムノグロブリン親和性リガンド
|
RS53864B1
(en)
|
2006-03-02 |
2015-08-31 |
Alexion Pharmaceuticals, Inc. |
EXTENDING ALOGRAPHIC SURVIVAL BY INHIBITING COMPLEMENT ACTIVITIES
|
ES2527695T3
(es)
|
2006-03-08 |
2015-01-28 |
Archemix Llc |
Aptámeros de unión a complemento y agentes anti-C5 útiles en el tratamiento de trastornos oculares
|
DK2359834T5
(en)
|
2006-03-15 |
2017-02-06 |
Alexion Pharma Inc |
Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
|
NZ591252A
(en)
|
2006-03-17 |
2012-06-29 |
Biogen Idec Inc |
Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
|
JP4294082B2
(ja)
|
2006-03-23 |
2009-07-08 |
協和発酵キリン株式会社 |
ヒトトロンボポエチン受容体に対するアゴニスト抗体
|
MX2008012146A
(es)
|
2006-03-28 |
2008-10-03 |
Biogen Idec Inc |
Anticuerpos anti-receptor 1 de factor de crecimiento tipo insulina (igf-1r) y uso de los mismos.
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
WO2007114325A1
(ja)
*
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
SG170837A1
(en)
|
2006-04-05 |
2011-05-30 |
Abbott Biotech Ltd |
Antibody purification
|
CN101495146B
(zh)
*
|
2006-04-07 |
2012-10-17 |
国立大学法人大阪大学 |
肌肉再生促进剂
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
MY157173A
(en)
|
2006-05-25 |
2016-05-13 |
Glaxo Group Ltd |
Modified humanised anti-interleukin-18
|
MX2008014804A
(es)
|
2006-06-02 |
2009-01-27 |
Regeneron Pharma |
Anticuerpos de afinidad elevada a receptor de il-6 humano.
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
DK2047863T3
(da)
|
2006-06-08 |
2013-09-16 |
Chugai Pharmaceutical Co Ltd |
Middel til forebyggelse eller behandling af inflammatoriske sygdomme
|
ES2415655T3
(es)
*
|
2006-06-15 |
2013-07-26 |
The Board Of Trustees Of The University Of Arkansas |
Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
|
CL2007001829A1
(es)
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
PT2059536E
(pt)
|
2006-08-14 |
2014-04-14 |
Xencor Inc |
Anticorpos otimizados que visam cd19
|
DE102006038844B4
(de)
|
2006-08-18 |
2018-03-22 |
Robert Bosch Gmbh |
Vorrichtung und Verfahren zur Ansteuerung von Personenschutzmittel
|
EA015916B1
(ru)
|
2006-09-05 |
2011-12-30 |
Эли Лилли Энд Компани |
Моноклональные антитела к миостатину и их применения
|
EP2066349B1
(en)
|
2006-09-08 |
2012-03-28 |
MedImmune, LLC |
Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
JP2008104147A
(ja)
|
2006-09-19 |
2008-05-01 |
Ricoh Co Ltd |
撮像装置、撮像システム、画像データ処理方法およびプログラム
|
CA3163418A1
(en)
|
2006-10-06 |
2008-05-22 |
Jeffrey S. Isenberg |
Prevention of tissue ischemia, related methods and compositions
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
WO2008121160A2
(en)
|
2006-11-21 |
2008-10-09 |
Xencor, Inc. |
Optimized antibodies that target cd5
|
CN100455598C
(zh)
|
2006-11-29 |
2009-01-28 |
中国抗体制药有限公司 |
功能人源化抗人cd20抗体及其应用
|
WO2008091798A2
(en)
|
2007-01-22 |
2008-07-31 |
Xencor, Inc. |
Optimized ca9 antibodies and methods of using the same
|
AU2008207898B2
(en)
|
2007-01-23 |
2012-05-03 |
Xencor, Inc |
Optimized CD40 antibodies and methods of using the same
|
TWI438208B
(zh)
|
2007-01-23 |
2014-05-21 |
Chugai Pharmaceutical Co Ltd |
抑制慢性排斥反應之藥劑
|
US20110236374A1
(en)
*
|
2007-01-24 |
2011-09-29 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
WO2008098115A2
(en)
|
2007-02-07 |
2008-08-14 |
Xencor, Inc. |
Optimized igf-1r antibodies and methods of using the same
|
EP2069404B1
(en)
*
|
2007-02-14 |
2011-01-05 |
Vaccinex, Inc. |
Humanized anti-cd100 antibodies
|
BRPI0807710B1
(pt)
|
2007-02-23 |
2021-12-14 |
Merck Sharp & Dohme Corp |
Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
|
BRPI0809026A2
(pt)
|
2007-03-20 |
2014-09-23 |
Lilly Co Eli |
Anticorpos antiesclerotina
|
CA2680760A1
(en)
|
2007-03-22 |
2008-09-25 |
Novartis Ag |
C5 antigens and uses thereof
|
CL2008001071A1
(es)
|
2007-04-17 |
2009-05-22 |
Smithkline Beecham Corp |
Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
|
GB0708002D0
(en)
|
2007-04-25 |
2007-06-06 |
Univ Sheffield |
Antibodies
|
BRPI0811857A2
(pt)
|
2007-05-14 |
2014-10-21 |
Biogen Idec Inc |
Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
|
EP2708557A1
(en)
|
2007-05-30 |
2014-03-19 |
Xencor, Inc. |
Method and compositions for inhibiting CD32B expressing cells
|
US20100291023A1
(en)
|
2007-05-31 |
2010-11-18 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
EP2164961B1
(en)
|
2007-06-25 |
2015-01-07 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Sequence based engineering and optimization of single chain antibodies
|
WO2009000099A2
(en)
|
2007-06-25 |
2008-12-31 |
Esbatech Ag |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
EP2179282B1
(en)
|
2007-06-29 |
2016-06-01 |
Quest Diagnostics Investments Incorporated |
Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
US20110105724A1
(en)
|
2007-08-16 |
2011-05-05 |
Stephanie Jane Clegg |
Novel compounds
|
WO2009032145A1
(en)
|
2007-08-28 |
2009-03-12 |
Biogen Idec Ma Inc. |
Anti-igf-1r antibodies and uses thereof
|
KR20100052545A
(ko)
|
2007-08-28 |
2010-05-19 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Igf―1r의 다중 에피토프에 결합하는 조성물
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
WO2009041734A1
(ja)
|
2007-09-26 |
2009-04-02 |
Kyowa Hakko Kirin Co., Ltd. |
ヒトトロンボポエチン受容体に対するアゴニスト抗体
|
PH12018501459A1
(en)
*
|
2007-09-26 |
2019-11-11 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
CL2008002885A1
(es)
|
2007-09-26 |
2010-07-02 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
|
MX369784B
(es)
|
2007-09-26 |
2019-11-21 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
EP2196541B1
(en)
*
|
2007-09-28 |
2012-11-07 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican-3 antibody having improved kinetics in plasma
|
KR101601986B1
(ko)
|
2007-10-02 |
2016-03-17 |
추가이 세이야쿠 가부시키가이샤 |
인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
|
KR100888133B1
(ko)
|
2007-10-02 |
2009-03-13 |
에스케이에너지 주식회사 |
4종의 금속성분으로 구성된 다성분계 비스무스몰리브데이트 촉매 제조방법 및 상기촉매를 이용하여1,3-부타디엔을 제조하는 방법
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
AU2008314687A1
(en)
|
2007-10-22 |
2009-04-30 |
Merck Serono S.A. |
Method for purifying Fc-fusion proteins
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
AR069333A1
(es)
|
2007-11-15 |
2010-01-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos
|
EP2241332A4
(en)
|
2007-12-05 |
2011-01-26 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT AGAINST PRITURE
|
EP2236604B1
(en)
|
2007-12-05 |
2016-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-nr10 antibody and use thereof
|
CA2709354C
(en)
|
2007-12-21 |
2014-06-17 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
SI2235059T1
(sl)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variante s spremenjeno vezjo na fcrn
|
CA2710439C
(en)
|
2008-01-18 |
2016-04-12 |
Stichting Sanquin Bloedvoorziening |
Methods for increasing the therapeutic efficacy of immunoglobulin g class 3 (igg3) antibodies
|
US20110183861A1
(en)
|
2008-01-29 |
2011-07-28 |
Ablynn N.V. |
Methods to stabilize proteins and polypeptides
|
AU2015227424A1
(en)
|
2008-04-11 |
2015-10-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
DK2708559T3
(en)
|
2008-04-11 |
2018-06-14 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
|
CA2722600C
(en)
*
|
2008-05-01 |
2014-01-21 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
EP2303311B1
(en)
|
2008-05-14 |
2018-08-01 |
Agriculture Victoria Services Pty Ltd |
Angiogenin for use in treating skeletal muscle disorders
|
KR101665729B1
(ko)
|
2008-06-05 |
2016-10-12 |
국립연구개발법인 고쿠리츠간켄큐센터 |
신경침윤 억제제
|
EP2815766B1
(en)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Compositions and methods for antibodies targeting complement protein C5
|
EP2331578B1
(en)
|
2008-09-17 |
2014-06-04 |
Xencor, Inc. |
Novel compositions and methods for treating ige-mediated disorders
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
JP5229888B2
(ja)
|
2008-09-30 |
2013-07-03 |
独立行政法人産業技術総合研究所 |
弱酸性域での易解離性を向上したプロテインa変異型タンパク質及び抗体捕捉剤
|
PE20110707A1
(es)
|
2008-10-14 |
2011-10-11 |
Genentech Inc |
Variantes de inmunoglobulinas
|
PT2894165T
(pt)
|
2008-11-10 |
2023-03-17 |
Alexion Pharma Inc |
Métodos e composições para o tratamento de distúrbios associados ao complemento
|
WO2010058860A1
(ja)
|
2008-11-18 |
2010-05-27 |
株式会社シノテスト |
試料中のc反応性蛋白質の測定方法及び測定試薬
|
NZ602166A
(en)
|
2008-11-25 |
2014-02-28 |
Alder Biopharmaceuticals Inc |
Antibodies to il-6 and use thereof
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
JP2012515556A
(ja)
|
2009-01-23 |
2012-07-12 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
|
US20100292443A1
(en)
*
|
2009-02-26 |
2010-11-18 |
Sabbadini Roger A |
Humanized platelet activating factor antibody design using anti-lipid antibody templates
|
RU2565809C2
(ru)
|
2009-03-19 |
2015-10-20 |
Чугаи Сейяку Кабусики Кайся |
Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
|
JP5717624B2
(ja)
*
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
JP5787446B2
(ja)
*
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
AR076875A1
(es)
|
2009-05-15 |
2011-07-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo contra receptor de la tirosina quinasa (anti-axl)
|
EP2435079A4
(en)
|
2009-05-26 |
2012-11-14 |
Univ Johns Hopkins |
NEW DESMINPHOSPHORYLATION ORTE FOR DIAGNOSIS AND INFLUENCING DISEASES
|
US8609097B2
(en)
|
2009-06-10 |
2013-12-17 |
Hoffmann-La Roche Inc. |
Use of an anti-Tau pS422 antibody for the treatment of brain diseases
|
RU2012102021A
(ru)
|
2009-06-23 |
2013-07-27 |
Алексион Фармасьютикалз, Инк. |
Биспецифические антитела, которые связываются с белками комплемента
|
US8945511B2
(en)
|
2009-06-25 |
2015-02-03 |
Paul Weinberger |
Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
|
CN102471378B
(zh)
|
2009-06-26 |
2014-04-02 |
瑞泽恩制药公司 |
容易地分离的具有天然免疫球蛋白形式的双特异性抗体
|
GB0914691D0
(en)
|
2009-08-21 |
2009-09-30 |
Lonza Biologics Plc |
Immunoglobulin variants
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
EP2481752B1
(en)
*
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
JP5734988B2
(ja)
|
2009-10-06 |
2015-06-17 |
メディミューン リミテド |
Rsv特異的結合分子
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
RU2583298C2
(ru)
|
2009-10-07 |
2016-05-10 |
Макродженикс, Инк. |
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
JP6095368B2
(ja)
|
2009-10-27 |
2017-03-15 |
ユセベ ファルマ ソシエテ アノニム |
機能改変するNav1.7抗体
|
CN101875696B
(zh)
|
2009-11-11 |
2012-02-08 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其制备方法与应用
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
AU329016S
(en)
|
2009-12-03 |
2009-12-22 |
Non Entity 49398 |
Induction system with integral air filter
|
MX2012007497A
(es)
|
2009-12-25 |
2012-08-01 |
Chugai Pharmaceutical Co Ltd |
Metodo para modificacion de polipeptidos para purificar multimeros de polipeptido.
|
JP6101489B2
(ja)
|
2010-01-28 |
2017-03-22 |
アブ バイオサイエンシズ インコーポレイテッド |
親和性が低下した抗体およびそれを作製する方法
|
EP2534256A4
(en)
|
2010-02-09 |
2013-07-24 |
Glaxosmithkline Llc |
NEW USES
|
TW201127310A
(en)
*
|
2010-02-11 |
2011-08-16 |
jin-zhu Chen |
Step-less finetuning buckle
|
WO2011103584A2
(en)
|
2010-02-19 |
2011-08-25 |
Xencor, Inc. |
Novel ctla4-ig immunoadhesins
|
MX2012010116A
(es)
|
2010-03-01 |
2013-02-26 |
Alexion Pharma Inc |
Metodos y composiciones para el tratamiento de la enfermedad de degos.
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
JP2011184418A
(ja)
|
2010-03-11 |
2011-09-22 |
Tokyo Institute Of Technology |
親和性可変抗体
|
SA111320266B1
(ar)
|
2010-03-11 |
2015-06-21 |
رينات نيوروساينس كوربوريشن |
أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
|
TW201206466A
(en)
|
2010-03-11 |
2012-02-16 |
Rinat Neuroscience Corp |
Antibodies with pH dependent antigen binding
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
BR112012027917A2
(pt)
|
2010-04-30 |
2017-11-28 |
Alexion Pharma Inc |
anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
WO2011149046A1
(ja)
|
2010-05-28 |
2011-12-01 |
独立行政法人国立がん研究センター |
膵癌治療剤
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
JP2013537425A
(ja)
|
2010-08-16 |
2013-10-03 |
アムジエン・インコーポレーテツド |
ミオスタチンに結合するポリペプチド、組成物および方法
|
WO2012033953A1
(en)
|
2010-09-08 |
2012-03-15 |
Halozyme, Inc. |
Methods for assessing and identifying or evolving conditionally active therapeutic proteins
|
JP6173911B2
(ja)
|
2010-09-10 |
2017-08-09 |
メディミューン リミテド |
抗体誘導体
|
CN103476793A
(zh)
|
2010-11-08 |
2013-12-25 |
基因技术公司 |
皮下施用的抗-il-6受体抗体
|
CN108715614A
(zh)
|
2010-11-30 |
2018-10-30 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
WO2012088247A2
(en)
|
2010-12-22 |
2012-06-28 |
Medimmune, Llc |
Anti-c5/c5a/c5adesr antibodies and fragments
|
US20140080153A1
(en)
|
2011-01-07 |
2014-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Method for improving physical properties of antibody
|
WO2012133782A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
BR112013021526B1
(pt)
|
2011-02-25 |
2021-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
|
WO2012132067A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
EP2686345B1
(en)
|
2011-03-16 |
2018-04-25 |
Amgen Inc. |
Fc variants
|
PL3404041T3
(pl)
|
2011-04-19 |
2020-12-14 |
Amgen Inc. |
Sposób leczenia osteoporozy
|
CN113461819B
(zh)
|
2011-04-29 |
2024-01-02 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
KR102024016B1
(ko)
|
2011-05-04 |
2019-11-04 |
오메로스 코포레이션 |
Masp-2 의존적 보체 활성화를 억제하는 조성물
|
KR20190105112A
(ko)
|
2011-05-21 |
2019-09-11 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
KR20140028013A
(ko)
|
2011-05-25 |
2014-03-07 |
머크 샤프 앤드 돔 코포레이션 |
개선된 특성을 갖는 Fc-함유 폴리펩티드를 제조하는 방법
|
US8961981B2
(en)
|
2011-06-20 |
2015-02-24 |
Saint Louis University |
Targeting the neuromuscular junction for treatment
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
MX366968B
(es)
|
2011-09-30 |
2019-08-01 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
|
US10024867B2
(en)
|
2011-09-30 |
2018-07-17 |
Chugai Seiyaku Kabushiki Kaisha |
Ion concentration-dependent binding molecule library
|
WO2013047752A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
抗原の消失を促進する抗原結合分子
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
JP6271251B2
(ja)
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
|
BR112014013081A2
(pt)
|
2011-11-30 |
2020-10-20 |
Chugai Seiyaku Kabushiki Kaisha |
veículo contendo fármaco em célula para formação de um complexo imune
|
US20160046693A1
(en)
|
2012-02-24 |
2016-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc gamma RIIB
|
ES2687974T3
(es)
|
2012-03-14 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Moléculas multiespecíficas de unión a antígeno y uso de las mismas
|
BR112014022855A2
(pt)
|
2012-03-16 |
2017-07-18 |
Regeneron Pharma |
animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano
|
EP2883449B1
(en)
|
2012-03-16 |
2018-02-07 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
HUE037613T2
(hu)
|
2012-03-29 |
2018-09-28 |
Novimmune Sa |
Anti-TLR4 antitestek és azok felhasználása
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗-hla-b*27抗體及其用途
|
JP5988659B2
(ja)
|
2012-04-09 |
2016-09-07 |
シャープ株式会社 |
送風機
|
WO2013166099A1
(en)
|
2012-05-01 |
2013-11-07 |
Glaxosmithkline Llc |
Novel antibodies
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
ES2856272T3
(es)
|
2012-05-30 |
2021-09-27 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígenos para eliminar antígenos agregados
|
RU2743463C2
(ru)
|
2012-05-30 |
2021-02-18 |
Чугаи Сейяку Кабусики Кайся |
Специфичная к ткани-мишени антигенсвязывающая молекула
|
SA113340642B1
(ar)
|
2012-06-15 |
2015-09-15 |
فايزر إنك |
أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
CA2881679C
(en)
|
2012-08-13 |
2021-01-26 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
US9133269B2
(en)
|
2012-08-24 |
2015-09-15 |
Anaptysbio, Inc. |
Humanized antibodies directed against complement protein C5
|
CA2882272C
(en)
|
2012-08-24 |
2023-08-29 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc region variant
|
EP3597747B1
(en)
|
2012-08-24 |
2023-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse fcgammarii-specific fc antibody
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
ES2879387T3
(es)
|
2012-09-13 |
2021-11-22 |
Bristol Myers Squibb Co |
Proteínas de dominio de armazón a base de fibronectina que se unen a miostatina
|
TW201418707A
(zh)
|
2012-09-21 |
2014-05-16 |
Alexion Pharma Inc |
補體組分c5拮抗劑之篩選分析
|
EP2916867A4
(en)
|
2012-11-06 |
2016-10-05 |
Scholar Rock Inc |
COMPOSITIONS AND METHOD FOR MODULATING CELL SIGNALING
|
AR094271A1
(es)
|
2012-12-21 |
2015-07-22 |
Aveo Pharmaceuticals Inc |
Anticuerpos anti-gdf15
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
BR112015017619A2
(pt)
|
2013-01-24 |
2017-11-21 |
Glaxosmithkline Ip Dev Ltd |
formulação líquida, uso de uma formulação, e, kit
|
EP2975055A4
(en)
|
2013-01-31 |
2016-11-02 |
Univ Seoul Nat R & Db Found |
C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES
|
US9481725B2
(en)
|
2013-03-14 |
2016-11-01 |
Alderbio Holdings, Llc |
Antibodies to HGF and compositions containing
|
US9321686B2
(en)
|
2013-03-15 |
2016-04-26 |
Forta Corporation |
Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
|
US20160032014A1
(en)
|
2013-03-15 |
2016-02-04 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
US20160031985A1
(en)
|
2013-03-15 |
2016-02-04 |
Katherine S. Bowdish |
Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
|
MX2015011430A
(es)
|
2013-03-15 |
2016-04-20 |
Amgen Inc |
Antagonismo de la miostatina en seres humanos.
|
AU2014232501C1
(en)
|
2013-03-15 |
2021-04-22 |
Xencor, Inc. |
Heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
ES2768648T3
(es)
|
2013-03-29 |
2020-06-23 |
Alexion Pharma Inc |
Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
RS61778B1
(sr)
|
2013-05-06 |
2021-06-30 |
Scholar Rock Inc |
Kompozicije i postupci za modulaciju faktora rasta
|
JP6416224B2
(ja)
|
2013-05-17 |
2018-10-31 |
セントル ナショナル デ ラ ルシュルシュ サイエンティフィーク(シーエヌアールエス) |
抗cxcl1抗体、抗cxcl7抗体および抗cxcl8抗体ならびにそれらの用途
|
RU2655439C2
(ru)
|
2013-05-31 |
2018-05-28 |
Займворкс Инк. |
Гетеромультимеры с уменьшенной или подавленной эффекторной функцией
|
CA2918795A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
BR112016002198A2
(pt)
|
2013-08-14 |
2017-09-12 |
Novartis Ag |
métodos de tratamento de miosite por corpos de inclusão esporádica
|
JP2016531910A
(ja)
|
2013-08-16 |
2016-10-13 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
移植前の臓器への補体阻害剤の投与による移植拒絶の処置
|
JP6456831B2
(ja)
|
2013-09-04 |
2019-01-23 |
プロテノバ株式会社 |
イムノグロブリン結合ドメイン多量体
|
EP2853898B1
(en)
|
2013-09-27 |
2017-01-04 |
Medizinische Hochschule Hannover |
Analysis of myostatin in serum
|
RU2016129517A
(ru)
|
2013-12-20 |
2018-01-25 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифические антитела к her2 и способы применения
|
WO2015111008A2
(en)
|
2014-01-27 |
2015-07-30 |
Novartis Ag |
Biomarkers predictive of muscle atrophy, method and use
|
SG11201606842RA
(en)
|
2014-02-20 |
2016-09-29 |
Allergan Inc |
Complement component c5 antibodies
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
CN106459192B
(zh)
|
2014-06-30 |
2021-08-03 |
默克专利股份公司 |
具有pH依赖性抗原结合的抗TNFa抗体
|
WO2016073879A2
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Transforming growth factor-related antibodies and uses thereof
|
CA3005158A1
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
CN106999589A
(zh)
|
2014-12-08 |
2017-08-01 |
诺华股份有限公司 |
用于治疗肌肉减少症的肌肉生长抑制素或激活素拮抗剂
|
JP6227191B1
(ja)
|
2014-12-19 |
2017-11-08 |
中外製薬株式会社 |
抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法
|
LT3233921T
(lt)
|
2014-12-19 |
2021-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antikūnai ir panaudojimo būdai
|
EP3247723A1
(en)
|
2015-01-22 |
2017-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
TWI805046B
(zh)
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
EP3277715A2
(en)
|
2015-03-31 |
2018-02-07 |
Alexion Pharmaceuticals, Inc. |
Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
|
MA49661A
(fr)
|
2015-04-15 |
2020-06-03 |
Regeneron Pharma |
Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
|
WO2016178980A1
(en)
|
2015-05-01 |
2016-11-10 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
|
WO2016209956A1
(en)
|
2015-06-26 |
2016-12-29 |
Alexion Pharmaceuticals, Inc. |
A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
|
US10940126B2
(en)
|
2015-07-03 |
2021-03-09 |
Camilla Svensson |
Inhibition of IL-8 in the treatment of pain and/or bone loss
|
EP3922645A1
(en)
|
2015-09-15 |
2021-12-15 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
TWI751300B
(zh)
|
2015-09-18 |
2022-01-01 |
日商中外製藥股份有限公司 |
Il-8 結合抗體及其用途
|
TW201718014A
(zh)
|
2015-10-12 |
2017-06-01 |
諾華公司 |
C5抑制劑於移植相關微血管病之用途
|
TWI747936B
(zh)
|
2015-12-18 |
2021-12-01 |
日商中外製藥股份有限公司 |
抗c5抗體及使用方法
|
CA3002422C
(en)
|
2015-12-18 |
2024-04-16 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
US10233252B2
(en)
|
2015-12-21 |
2019-03-19 |
Wisconsin Alumni Research Foundation |
pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
WO2017120523A2
(en)
|
2016-01-08 |
2017-07-13 |
Scholar Rock, Inc. |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
EP3402816A1
(en)
|
2016-01-11 |
2018-11-21 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment
|
MA53248A
(fr)
|
2016-01-25 |
2022-02-16 |
Takeda Pharmaceuticals Co |
Anticorps anti-c5 à commutation ph améliorée
|
SI3368069T1
(sl)
|
2016-06-13 |
2021-03-31 |
Scholar Rock, Inc. |
Uporaba zaviralcev miostatina in kombinirane terapije
|
IL309975A
(en)
|
2016-06-14 |
2024-03-01 |
Regeneron Pharma |
Antibodies against C5 and their uses
|
KR101822352B1
(ko)
|
2016-06-17 |
2018-01-25 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체 및 사용 방법
|
UA126561C2
(uk)
|
2016-06-17 |
2022-11-02 |
Чугаі Сейяку Кабусікі Кайся |
Застосування антитіла проти с5
|
JP6527643B2
(ja)
|
2016-08-05 |
2019-06-05 |
中外製薬株式会社 |
Il−8関連疾患の治療用又は予防用組成物
|
EP3574010A4
(en)
|
2017-01-30 |
2020-12-16 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
|
KR20230043247A
(ko)
|
2017-01-31 |
2023-03-30 |
추가이 세이야쿠 가부시키가이샤 |
C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
|
JP7211961B2
(ja)
|
2017-03-14 |
2023-01-24 |
ファイヴ プライム セラピューティクス インク |
酸性pHでVISTAに結合する抗体
|
SG11201908056QA
(en)
|
2017-03-16 |
2019-09-27 |
Medimmune Ltd |
Anti-par2 antibodies and uses thereof
|
TWI826364B
(zh)
|
2017-04-03 |
2023-12-21 |
德商因夫萊亞斯有限公司 |
活性抑制劑於發炎性疾病之治療
|
CN111868081A
(zh)
|
2017-10-26 |
2020-10-30 |
亚力兄制药公司 |
用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
|
CN111683672A
(zh)
|
2017-12-04 |
2020-09-18 |
Ra制药公司 |
补体活性调节剂
|
EP3829628B1
(en)
|
2018-08-01 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease
|
SG11202110986YA
(en)
|
2019-04-10 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Method for purifying fc region-modified antibody
|